60 Degrees Pharmaceuticals, Inc. (SXTP) Stock Price & Analysis
60 Degrees Pharmaceuticals, Inc. (SXTP) — MoonshotScore 18/100 (Weak band), calculated Nov 18, 2026. Price $0.5379 (+0.71%), as of the Nov 18, 2026 trading session; market cap $2.41M.
Educational signal · not a buy or sell recommendation · How to read this
60 Degrees Pharmaceuticals, Inc. · SXTP
is a specialty pharmaceutical company focused on developing and commercializing therapies for infectious diseases. Their lead product, Arakoda, is used for malaria prevention, and they have ongoing clinical trials for other infectious diseases.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · 60 Degrees Pharmaceuticals (SXTP)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a fragile balance sheet, weak growth and an expensive valuation, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Fading; Momentum: Slipping.
- EPS beat 0 of the last 4 reports
- Altman Z -26.30 · Piotroski F 3
Holding back: weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 19 | Weak | |
| 19 | Weak | |
| 23 | Weak | |
| 23 | Weak | |
| 18 | Weak | |
| 18 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.5379 | |
| Change on the day | +0.71% | |
| Market capitalisation | $2.41M | — |
| Shares traded on the day | 34.0K |
Price & events
Other perspectives
Council score for 60 Degrees Pharmaceuticals (SXTP): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is 60 Degrees Pharmaceuticals (SXTP), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. 60 Degrees Pharmaceuticals, Inc. (SXTP) is the company analyzed here. It employs 3 people. The market values it at $2.41M.
What do the latest results show for 60 Degrees Pharmaceuticals (SXTP)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Jun 2025 | $100,932 | -$2M | -$4.71 (diluted) |
| Q3 FY2025 | $437,602 | -$2M | -$2.52 (diluted) |
| Q4 FY2025 | $303,385 | -$1M | — |
| Q1 FY2026 | $162,092 | -$2M | -$1.21 (diluted) |
What are the financial strengths and risks for 60 Degrees Pharmaceuticals (SXTP)?
Short answer · as of
What is holding it back is weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -26.30 · Piotroski F 3. Trailing ratios: current ratio 1.17.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -26.30 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 1 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
How does 60 Degrees Pharmaceuticals compare with its peers?
Short answer
60 Degrees Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $3.02 Nov 18, 2026 | $255M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.96 Nov 18, 2026 | $186M | 69 5-pillar Nov 18, 2026 | |
| $12.48 Nov 18, 2026 | $884M | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $29.68 Nov 18, 2026 | $993M | 64 5-pillar Nov 18, 2026 | |
| $8.32 Nov 18, 2026 | $813M | 63 5-pillar Nov 18, 2026 | |
| 60 Degrees Pharmaceuticals (SXTP) — this page | $0.5379 | $2.41M | 18 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held SXTP in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported SXTP in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about 60 Degrees Pharmaceuticals (SXTP)?
- 60 Degrees Pharmaceuticals Announces Investor Webinar on Tafenoquine Development and ARAKODA Commercialization
- Ironwood Pharmaceuticals (IRWD) Beats Q3 Earnings Estimates
- Join 60 Degrees Pharmaceuticals' Live Investor Webinar: Advancing Tafenoquine for Babesiosis While Expanding ARAKODA(R) Commercialization
What Investors Ask About 60 Degrees Pharmaceuticals (SXTP)
These answers are editorial: 1 of these 9 answers is drawn from the SXTP research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for SXTP?
SXTP carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is SXTP a good stock to buy?
Stock Expert AI does not rate SXTP buy, sell or hold. 60 Degrees Pharmaceuticals, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the SXTP stock price today?
The last price recorded for 60 Degrees Pharmaceuticals, Inc. (SXTP), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about SXTP stock?
There is currently no available analyst coverage for SXTP stock. Given the company's small market capitalization and limited trading volume, it may not be actively followed by major research firms.
What are the key factors to evaluate for SXTP?
(SXTP) holds a MoonshotScore in the low range. Analysts target $3.70 (+588%). These viral infections pose ongoing global health challenges, creating a demand for effective treatments. Not financial advice.
How frequently does SXTP data refresh on this page?
SXTP's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven SXTP's recent stock price performance?
(SXTP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on infectious diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SXTP overvalued or undervalued right now?
(SXTP) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SXTP before investing?
Before investing in 60 Degrees Pharmaceuticals, Inc. (SXTP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 10 figures on this page — 6 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com